Oruka Therapeutics CMO sells 7,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves exercised 3,500 employee stock options at $6.84 and 3,500 employee warrants at $7.80 on November 16, 2026, acquiring 7,000 common shares. She also sold 7,000 common shares that day in six reported sale entries, at weighted-average prices from $99.5150 to $105.8560 per share. The sales were effected under a Rule 10b5-1 trading plan entered into on September 19, 2025.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F8 | 3,500 | $0.00 | $0.00 |
| Exercise | Employee Warrant (right to buy) F9 | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $6.84 | $24K |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock F1, F2 | 2,600 | $99.515 | $259K |
| Sale | Common Stock F1, F3 | 1,500 | $100.4792 | $151K |
| Sale | Common Stock F1, F4 | 1,900 | $101.5268 | $193K |
| Sale | Common Stock F1, F5 | 300 | $102.47 | $31K |
| Sale | Common Stock F1, F6 | 200 | $103.36 | $21K |
| Sale | Common Stock F1, F7 | 500 | $105.856 | $53K |
Footnotes (9)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.03 to $99.98, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.04, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.11 to $102.09, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.18 to $102.95, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.26 to $103.46, inclusive.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.48 to $106.20, inclusive.
- F8. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
- F9. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Employee Stock Option (right to buy) financial
Employee Warrant (right to buy) financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options and warrants did ORKA's chief medical officer exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.